Summer 2010
PATHWAY TO
SUCCESS Selexys Pharmaceuticals targets inflammatory disease with Oklahoma-developed drugs
RURAL ROOTS
Durant-based REI takes economic development mission statewide
CAPITAL MILESTONE
Historic proof-of-concept funding awarded to water remediation business
GOVERNOR’S CUP ROADMAP Pointing college students in the right direction
The Selexys Pharmaceuticals management trio of (from left), David Falconer, vice president of business and development; Scott Rollins, chief executive officer; and Rick Alvarez, vice president of operations and research, have the Oklahoma City company on track to begin human clinical trials by early 2011 for drugs to treat Sickle Cell and Crohn’s diseases.